产品说明书
Latanoprost
 |
同义名 : | 拉坦前列素 ;PHXA41;Latanoprost Analytical Reference Standard;17-phenyl-13,14-dihydro trinor Prostaglandin F2α isopropyl ester;17-phenyl-13,14-dihydro trinor PGF2α isopropyl ester;Xalatan |
| CAS号 : | 130209-82-4 | |
| 货号 : | A699649 | |
| 分子式 : | C26H40O5 | |
| 纯度 : | 97% | |
| 分子量 : | 432.59 | |
| MDL号 : | MFCD00216074 | |
| 存储条件： |
粉末 Sealed in dry,Store in freezer, under -20°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 105 mg/mL(242.72 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO H2O: 100 mg/mL(231.16 mM)，配合低频超声助溶 无水乙醇: 100 mg/mL(231.16 mM)，配合低频超声助溶，注意：无水乙醇开封后，易挥发，也会吸收空气中的水分，导致溶解能力下降，请避免使用开封较久的乙醇 |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Latanoprost (PHXA41) is a prostaglandin F2α analogue utilized in glaucoma research. It can penetrate the cornea and is metabolized by esterase into latanoprost acid. Latanoprost acid acts as an F-prostaglandin (FP) receptor agonist, effectively lowering intraocular pressure (IOP) by enhancing aqueous humor outflow through the uvea[1]. | ||
| 作用机制 | Latanoprost is a PGF2α analogue.[3] | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT00442312 | Glaucoma | Phase 4 | Unknown | - | Taiwan ... 展开 >> Allergan Taipei, Taiwan 收起 << |
| NCT03762369 | Primary Open-angle Glaucoma ... 展开 >> Ocular Hypertension 收起 << | Phase 3 | Not yet recruiting | May 30, 2022 | Korea, Republic of ... 展开 >> Seoul National University Hosipital Seoul, Jongno, Korea, Republic of 收起 << |
| NCT01433900 | Glaucoma | Phase 3 | Unknown | June 2014 | Italy ... 展开 >> San Paolo Hospital Recruiting Milano, Italy, 20142 Principal Investigator: Luca Rossetti, MD Principal Investigator: Paolo Fogagnolo, MD 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.31mL 0.46mL 0.23mL |
11.56mL 2.31mL 1.16mL |
23.12mL 4.62mL 2.31mL |
| 参考文献 |
|---|